FONT-SIZE Plus   Neg

GSK Submits Supplemental NDAs To FDA For Dabrafenib/trametinib Combination

U.K.-based drug maker GlaxoSmithKline plc (GSK, GSK.L) Tuesday announced submission of supplemental New Drug Applications or NDAs to the U.S. Food and Drug Administration or FDA for use of a BRAF inhibitor, dabrafenib, in combination with a MEK inhibitor trametinib. These applications are based from a randomised Phase I/II study comparing dabrafenib monotherapy to combination therapy with dabrafenib and trametinib in patients with BRAF V600E and V600K mutation positive metastatic melanoma.

The use of these drugs in combination is investigational, the company said, and is not approved anywhere else. European review of the MAA submission for trametinib, both as monotherapy and in combination with dabrafenib, is ongoing. CHMP has reverted from the accelerated assessment review process to standard timelines to allow sufficient time for review of the submission.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Software giant Microsoft Corp. (MSFT), Tuesday reported a profit for the first quarter that trumped analysts' estimates, as CEO Satya Nadella's strategy seems to be working reflected by strong growth in cloud business. Microsoft stock spiked up over 5 percent in after hours trading. Redmond, Washington-based... In order to make Facebook more user-friendly, the social media giant introduced a few attractive new features. Recommendation tool, call-to-action buttons, and new section pages are expected to attract more users in a world where there are more mobiles than human beings. Starbucks Coffee Co. said Thursday that it plans to open a Reserve Roastery in Japan in 2018. This will be the coffee giant's fourth Roastery location globally. The new location will be located in Tokyo's upscale Nakameguro district, known for its exclusive boutiques and art galleries.
comments powered by Disqus
Follow RTT